News Alert: Chimerix Inc. (NASDAQ: CMRX)

Dorothy Owen

I am Dorothy Owen and I give “Seeking Review” an insight into the most recent news hitting the “Healthcare” sector in Wall Street.

I have been an independent financial adviser for over 11 years in the city and in recent years turned my experience in finance and passion for journalism into a full time role. I perform analysis of Companies and publicize valuable information for shareholder community.

Address: 454 Cottrill Lane, Saint Louis, MO 63108, USA
Phone: (+1) 314-388-9712
Email: dorothy.owen@seekingreview.com
Dorothy Owen

DURHAM, N.C., August 13, 2019 – Shares of Chimerix Inc. (NASDAQ: CMRX) inclined 3.86% to $2.96. The stock grabbed the investor’s attention and traded 343.088K shares as compared to its average daily volume of 418.51K shares. The stock’s institutional ownership stands at 63.70%.

Chimerix (CMRX) reported a net loss of $17.70M, or $0.35 per basic and diluted share, for the first quarter of 2019. During the same period in 2018, Chimerix recorded a net loss of $19.80M, or $0.42 per basic and diluted share.

Revenues for the first quarter of 2019 increased to $2.40M, contrast to $0.80M for the same period in 2018. Research and development expenses reduced to $13.50M for the first quarter of 2019, contrast to $14.40M for the same period in 2018. General and administrative expenses increased to $7.70M for the first quarter of 2019, contrast to $6.70M for the same period in 2018. Loss from operations was $18.80M for the first quarter of 2019, contrast to a loss from operations of $20.30M for the same period in 2018.

Chimerix’s balance sheet at March 31, 2019 included $171.60M of capital available to fund operations, no debt, and about 51.00M outstanding shares of common stock. Chimerix presently anticipates ending 2019 with about $140.0M in capital to fund operations which will reflect payments related to the close-out of the oral and intravenous clinical trials and severance costs from the restructuring described above.

CMRX has a market value of $184.56M while its EPS was booked as $-1.37 in the last 12 months. The stock has 62.35M shares outstanding. Beta value of the company was 1.25; beta is used to measure riskiness of the security. Analyst recommendation for this stock stands at 3.00.

Dorothy Owen

Dorothy Owen

I am Dorothy Owen and I give “Seeking Review” an insight into the most recent news hitting the “Healthcare” sector in Wall Street. I have been an independent financial adviser for over 11 years in the city and in recent years turned my experience in finance and passion for journalism into a full time role. I perform analysis of Companies and publicize valuable information for shareholder community. Address: 454 Cottrill Lane, Saint Louis, MO 63108, USA Phone: (+1) 314-388-9712 Email: dorothy.owen@seekingreview.com